Consistently, we found that depletion of the ECT2-Ex5+ isoform (as well as depletion of ZRANB2 or SYF2) did not affect Doxo survival in two triple-negative breast cancer cell lines (Supplementary Figure S9). Here, ZRANB2 is linked to triple-negative breast carcinoma.